Ultragenyx Pharmaceutical Inc. (RARE)
USD 39.3
(0.85%)
USD 39.3
(0.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 958.24 Million USD | -2.61% |
| 2022 | 983.92 Million USD | 37.2% |
| 2021 | 717.13 Million USD | 20.52% |
| 2020 | 595.01 Million USD | 14.67% |
| 2019 | 518.87 Million USD | 23.04% |
| 2018 | 421.72 Million USD | 27.2% |
| 2017 | 331.55 Million USD | 33.62% |
| 2016 | 248.14 Million USD | 67.96% |
| 2015 | 147.73 Million USD | 160.2% |
| 2014 | 56.77 Million USD | 75.89% |
| 2013 | 32.28 Million USD | 101.94% |
| 2012 | 15.98 Million USD | 143.64% |
| 2011 | 6.56 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 233.24 Million USD | -5.87% |
| 2024 Q1 | 247.8 Million USD | 4.39% |
| 2023 FY | 958.24 Million USD | -2.61% |
| 2023 Q3 | 232.16 Million USD | -5.76% |
| 2023 Q1 | 242.34 Million USD | -0.54% |
| 2023 Q2 | 246.35 Million USD | 1.65% |
| 2023 Q4 | 237.39 Million USD | 2.25% |
| 2022 Q3 | 307.13 Million USD | 37.94% |
| 2022 Q4 | 243.65 Million USD | -20.67% |
| 2022 FY | 983.92 Million USD | 37.2% |
| 2022 Q1 | 210.46 Million USD | 15.36% |
| 2022 Q2 | 222.66 Million USD | 5.8% |
| 2021 Q4 | 182.44 Million USD | 9.05% |
| 2021 FY | 717.13 Million USD | 20.52% |
| 2021 Q1 | 200.77 Million USD | 10.23% |
| 2021 Q2 | 166.61 Million USD | -17.01% |
| 2021 Q3 | 167.3 Million USD | 0.41% |
| 2020 Q2 | 122.96 Million USD | -23.38% |
| 2020 Q4 | 182.14 Million USD | 40.72% |
| 2020 Q1 | 160.47 Million USD | 28.45% |
| 2020 FY | 595.01 Million USD | 14.67% |
| 2020 Q3 | 129.43 Million USD | 5.27% |
| 2019 Q2 | 135.85 Million USD | 16.18% |
| 2019 FY | 518.87 Million USD | 23.04% |
| 2019 Q1 | 116.93 Million USD | 10.22% |
| 2019 Q4 | 124.93 Million USD | -11.49% |
| 2019 Q3 | 141.15 Million USD | 3.9% |
| 2018 Q3 | 101.13 Million USD | -5.97% |
| 2018 FY | 421.72 Million USD | 27.2% |
| 2018 Q1 | 106.93 Million USD | 7.75% |
| 2018 Q2 | 107.55 Million USD | 0.57% |
| 2018 Q4 | 106.09 Million USD | 4.9% |
| 2017 FY | 331.55 Million USD | 33.62% |
| 2017 Q1 | 69.95 Million USD | -0.85% |
| 2017 Q2 | 78.44 Million USD | 12.13% |
| 2017 Q3 | 83.91 Million USD | 6.97% |
| 2017 Q4 | 99.24 Million USD | 18.28% |
| 2016 Q1 | 53.62 Million USD | -4.52% |
| 2016 Q4 | 70.55 Million USD | 7.07% |
| 2016 Q3 | 65.89 Million USD | 13.47% |
| 2016 Q2 | 58.07 Million USD | 8.3% |
| 2016 FY | 248.14 Million USD | 67.96% |
| 2015 Q3 | 39.93 Million USD | 32.49% |
| 2015 Q2 | 30.14 Million USD | 40.18% |
| 2015 Q1 | 21.5 Million USD | 26.91% |
| 2015 FY | 147.73 Million USD | 160.2% |
| 2015 Q4 | 56.15 Million USD | 40.62% |
| 2014 Q1 | 10.33 Million USD | 8.55% |
| 2014 Q4 | 16.94 Million USD | 7.0% |
| 2014 Q3 | 15.83 Million USD | 15.91% |
| 2014 Q2 | 13.66 Million USD | 32.13% |
| 2014 FY | 56.77 Million USD | 75.89% |
| 2013 Q1 | 6.74 Million USD | 44.23% |
| 2013 Q3 | 7.76 Million USD | -5.89% |
| 2013 Q4 | 9.52 Million USD | 22.73% |
| 2013 FY | 32.28 Million USD | 101.94% |
| 2013 Q2 | 8.24 Million USD | 22.23% |
| 2012 Q4 | 4.67 Million USD | 0.0% |
| 2012 FY | 15.98 Million USD | 143.64% |
| 2011 FY | 6.56 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | -1200.801% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -197.816% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 46.766% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -9542.606% |
| Apollomics, Inc. | 54.14 Million USD | -1669.945% |
| 180 Life Sciences Corp. | 13.47 Million USD | -7009.983% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -2953.982% |
| Bicycle Therapeutics plc | 216.92 Million USD | -341.748% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1031.13% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -457.439% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1938.565% |
| Chimerix, Inc. | 93.38 Million USD | -926.082% |
| CRISPR Therapeutics AG | 463.49 Million USD | -106.744% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2741.105% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -722.862% |
| Fortress Biotech, Inc. | 200.19 Million USD | -378.657% |
| Fortress Biotech, Inc. | 200.19 Million USD | -378.657% |
| Gritstone bio, Inc. | 148.37 Million USD | -545.833% |
| Allakos Inc. | 196.05 Million USD | -388.762% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1648.755% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -572.629% |
| Cytokinetics, Incorporated | 173.61 Million USD | -451.948% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -3601.943% |
| Innoviva, Inc. | 132.15 Million USD | -625.1% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -12357.33% |
| NLS Pharmaceutics AG | 11.8 Million USD | -8015.888% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -654.158% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -7431635.691% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -834.347% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -978.307% |
| ImmuCell Corporation | 9.61 Million USD | -9863.73% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -507.201% |
| Incyte Corporation | 1.19 Billion USD | 19.508% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -622.905% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -14141.142% |
| Mustang Bio, Inc. | 48.5 Million USD | -1875.728% |
| MiMedx Group, Inc. | 229.72 Million USD | -317.125% |
| MEI Pharma, Inc. | 34.78 Million USD | -2654.774% |
| MacroGenics, Inc. | 217.21 Million USD | -341.152% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -10750.668% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2573.534% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -5255.581% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -496.89% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -457.607% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -4050.309% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -5932.028% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -9216.947% |
| NextCure, Inc. | 67.63 Million USD | -1316.751% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1671.908% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -3136.668% |
| Onconetix, Inc. | 34.9 Million USD | -2645.112% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -7418.029% |
| Opthea Limited | 191.96 Million USD | -399.172% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1505.828% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -34725.31% |
| PDS Biotechnology Corporation | 43.04 Million USD | -2126.142% |
| Precigen, Inc. | 84.18 Million USD | -1038.319% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -1220.519% |
| Prime Medicine, Inc. | 186.63 Million USD | -413.423% |
| PureTech Health plc | 144.59 Million USD | -562.703% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -269.041% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 65.963% |
| Replimune Group, Inc. | 234.77 Million USD | -308.159% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -10969.484% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -635.626% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -4834.713% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -92.124% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3842.335% |
| Sesen Bio, Inc. | 78.38 Million USD | -1122.551% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -319.034% |
| Solid Biosciences Inc. | 104.31 Million USD | -818.61% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -316.713% |
| SciSparc Ltd. | 9.01 Million USD | -10534.203% |
| Sutro Biopharma, Inc. | 243 Million USD | -294.326% |
| TG Therapeutics, Inc. | 198.47 Million USD | -382.805% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -689.286% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -12743.426% |
| Travere Therapeutics, Inc. | 472 Million USD | -103.018% |
| UroGen Pharma Ltd. | 138.88 Million USD | -589.943% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1257.407% |
| XOMA Corporation | 46.46 Million USD | -1962.389% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -279.426% |
| AbCellera Biologics Inc. | 275.23 Million USD | -248.16% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1588.275% |
| Cassava Sciences, Inc. | 105.95 Million USD | -804.374% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -6789.092% |
| Precision BioSciences, Inc. | 92.46 Million USD | -936.358% |
| Dyadic International, Inc. | 9.15 Million USD | -10369.571% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -11418.788% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -4206.152% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -3128.381% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -630.411% |
| IGM Biosciences, Inc. | 265.59 Million USD | -260.798% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -791.211% |
| Acelyrin, Inc. | 422.06 Million USD | -127.039% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -5241.702% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1036.402% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -14134.343% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -291.115% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -3014.127% |
| Senti Biosciences, Inc. | 94.7 Million USD | -911.824% |
| Mesoblast Limited | 5.9 Million USD | -16135.988% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -292.528% |
| ChromaDex Corporation | 56.37 Million USD | -1599.654% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2775.025% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -376.468% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -11815.683% |
| Seer, Inc. | 110.49 Million USD | -767.271% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -468.909% |
| Novavax, Inc. | 779.12 Million USD | -22.99% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -6007.463% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -277.198% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1733.932% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -287.738% |
| Celcuity Inc. | 66.23 Million USD | -1346.842% |
| ContextLogic Inc. | 387 Million USD | -147.609% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -470.974% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2826.306% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 70.566% |
| Amarin Corporation plc | 272.35 Million USD | -251.835% |
| AnaptysBio, Inc. | 181.56 Million USD | -427.763% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -3218.263% |
| Aptorum Group Limited | 10.56 Thousand USD | -9069065.247% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -764.322% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -114.981% |
| Ardelyx, Inc. | 169.93 Million USD | -463.884% |
| Celularity Inc. | 215.05 Million USD | -345.577% |
| Omeros Corporation | 94.75 Million USD | -911.333% |
| Humacyte, Inc. | 23.49 Million USD | -3978.172% |
| Immunocore Holdings plc | 308.04 Million USD | -211.079% |
| IO Biotech, Inc. | 91.44 Million USD | -947.918% |
| GT Biopharma, Inc. | 13.57 Million USD | -6958.397% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -1183.482% |
| Summit Therapeutics Inc. | 87.68 Million USD | -992.818% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -3151.715% |
| Pulmatrix, Inc. | 22.03 Million USD | -4248.162% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -73.732% |
| Evogene Ltd. | 27.79 Million USD | -3348.176% |
| CorMedix Inc. | 48.95 Million USD | -1857.294% |
| BioLineRx Ltd. | 50.8 Million USD | -1786.241% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2711.348% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2826.842% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 26.954% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1370.202% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -744.502% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -159.961% |
| NLS Pharmaceutics AG | 11.8 Million USD | -8015.888% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3842.335% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -454.317% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -2461.612% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -3627.431% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -675.576% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1053.779% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1703.714% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -11236.542% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2751.131% |
| bluebird bio, Inc. | 240.23 Million USD | -298.884% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 45.126% |
| DBV Technologies S.A. | 92.16 Million USD | -939.766% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -290.87% |
| Galecto, Inc. | 35.62 Million USD | -2589.668% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -2485.387% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1443.52% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -335.904% |
| GlycoMimetics, Inc. | 39.28 Million USD | -2339.203% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -224.039% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1339.113% |
| Clene Inc. | 41.07 Million USD | -2233.036% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -172.192% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1730.254% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -6549.709% |
| Soligenix, Inc. | 7.79 Million USD | -12192.715% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1608.99% |
| Kura Oncology, Inc. | 165.8 Million USD | -477.94% |
| Surrozen, Inc. | 18.55 Million USD | -5065.757% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -736.847% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -38513.513% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -789.755% |
| Autolus Therapeutics plc | 196.72 Million USD | -387.098% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1031.918% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -4843.755% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -536.557% |
| GRI Bio, Inc. | 11.33 Million USD | -8357.617% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -13481.188% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -1082.117% |
| INmune Bio, Inc. | 29.89 Million USD | -3105.272% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -455.332% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2276.943% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -5896.785% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -11537.781% |
| Jaguar Health, Inc. | 42.01 Million USD | -2180.728% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -5987.379% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1443.122% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2829.078% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -247.578% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -217.879% |
| Verastem, Inc. | 92.08 Million USD | -940.624% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -415.95% |
| Histogen Inc. | 14.27 Million USD | -6614.182% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -5871.084% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -27.074% |
| Surrozen, Inc. | 18.55 Million USD | -5065.757% |
| Organovo Holdings, Inc. | 14.91 Million USD | -6324.727% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -18725.218% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -12454.274% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -437.931% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1877.892% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -6135.925% |
| Kronos Bio, Inc. | 128.11 Million USD | -647.942% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1123.222% |
| Synaptogenix, Inc. | 8.31 Million USD | -11425.918% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -6469.642% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -624.984% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -278.67% |
| Exelixis, Inc. | 1.58 Billion USD | 39.61% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -312.949% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -12.049% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1291.569% |
| ESSA Pharma Inc. | 32.13 Million USD | -2882.028% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -5757.184% |
| Avid Bioservices, Inc. | 25.99 Million USD | -3586.136% |
| Insmed Incorporated | 949.26 Million USD | -0.947% |
| MediWound Ltd. | 18.86 Million USD | -4978.694% |
| OmniAb, Inc. | 83.89 Million USD | -1042.199% |
| Alector, Inc. | 248.8 Million USD | -285.145% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -308.969% |
| Zai Lab Limited | 547.47 Million USD | -75.03% |
| AlloVir, Inc. | 180.93 Million USD | -429.615% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -140.371% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -765.001% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1027.47% |
| Immunic, Inc. | 99.22 Million USD | -865.752% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -502.626% |
| Veracyte, Inc. | 357.93 Million USD | -167.717% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 89.371% |
| FibroGen, Inc. | 398.11 Million USD | -140.697% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6643.476% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -269.374% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -13811.954% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -13347.713% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -3603.66% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -202.723% |
| Fortrea Holdings Inc. | 457.3 Million USD | -109.545% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1665.445% |
| XBiotech Inc. | 37.51 Million USD | -2454.647% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1291.569% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -466.083% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -2430.429% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -4540.651% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -574.533% |
| Agenus Inc. | 78.18 Million USD | -1125.648% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -867.195% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -765.501% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -3222.059% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -122.517% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -4195.475% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -499.703% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -17225.204% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -3663.887% |
| Lantern Pharma Inc. | 17.87 Million USD | -5260.057% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -2128.484% |
| Ainos, Inc. | 12.95 Million USD | -7298.077% |
| Pluri Inc. | 22.48 Million USD | -4162.669% |
| Prothena Corporation plc | 282.4 Million USD | -239.316% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -379.071% |
| Rallybio Corporation | 78.93 Million USD | -1114.017% |
| Kodiak Sciences Inc. | 277.32 Million USD | -245.537% |
| Cue Biopharma, Inc. | 19.54 Million USD | -4803.531% |
| MeiraGTx Holdings plc | 151.07 Million USD | -534.274% |
| Annexon, Inc. | 143.72 Million USD | -566.733% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -4082.845% |
| Moderna, Inc. | 6.39 Billion USD | 85.013% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -28166.903% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -1003.146% |
| Blueprint Medicines Corporation | 722.86 Million USD | -32.563% |
| Immix Biopharma, Inc. | 16.14 Million USD | -5836.691% |
| CalciMedica, Inc. | 21.81 Million USD | -4292.208% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -568.649% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -459.414% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -428.54% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -224.896% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2671.505% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -1220.792% |
| Nutriband Inc. | 5.73 Million USD | -16611.594% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -2097.161% |
| Vor Biopharma Inc. | 126.03 Million USD | -660.297% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 19.419% |
| Alkermes plc | 996.24 Million USD | 3.814% |
| ProKidney Corp. | 151.52 Million USD | -532.415% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -1191.875% |
| Arcellx, Inc. | 200.19 Million USD | -378.648% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -56.009% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -535.865% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -2416.936% |
| Atai Life Sciences N.V. | 125.78 Million USD | -661.814% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -1073.758% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -1077.079% |
| MediciNova, Inc. | 10.9 Million USD | -8691.052% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -643.866% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -13099.874% |
| GeoVax Labs, Inc. | 6.02 Million USD | -15811.997% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -101.16% |
| Biomea Fusion, Inc. | 126.13 Million USD | -659.7% |
| RenovoRx, Inc. | 11.39 Million USD | -8308.635% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -401.467% |
| Geron Corporation | 70.44 Million USD | -1260.355% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3374.179% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -617.305% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -295.705% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -265.677% |
| Royalty Pharma plc | 862.4 Million USD | -11.114% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -360.709% |
| Imunon, Inc. | 20.31 Million USD | -4618.011% |
| BioAtla, Inc. | 129.68 Million USD | -638.893% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1028.439% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -2194.765% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -361.113% |
| Structure Therapeutics Inc. | 102.77 Million USD | -832.375% |
| 89bio, Inc. | 151.2 Million USD | -533.745% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -761.959% |
| aTyr Pharma, Inc. | 12.97 Million USD | -7283.065% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -824.45% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -276.132% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -11550.695% |
| Akari Therapeutics, Plc | 16.8 Million USD | -5601.821% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -42039.87% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -220.144% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -454.32% |
| Liquidia Corporation | 87.98 Million USD | -989.116% |
| Entera Bio Ltd. | 8.86 Million USD | -10715.44% |
| GH Research PLC | 41.22 Million USD | -2224.603% |
| Vericel Corporation | 142.04 Million USD | -574.632% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -4150.568% |
| Xencor, Inc. | 306.97 Million USD | -212.156% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -19322.872% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -5896.785% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -4576.687% |
| Vaxcyte, Inc. | 468.04 Million USD | -104.736% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1958.889% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -399.618% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -14141.142% |
| Portage Biotech Inc. | 18.19 Million USD | -5165.388% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -13099.874% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -812.956% |
| OncoCyte Corporation | 25.63 Million USD | -3637.754% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -15620.305% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -8263.82% |
| Purple Biotech Ltd. | -22.46 Million USD | 4365.136% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -3186.511% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -3005.246% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -279.53% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -5714.612% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -3133.937% |
| United Therapeutics Corporation | 885.1 Million USD | -8.264% |
| HilleVax, Inc. | 133.34 Million USD | -618.623% |
| Silo Pharma, Inc. | 3.92 Million USD | -24333.534% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -24208.38% |
| Pharming Group N.V. | 225.49 Million USD | -324.961% |
| Tharimmune, Inc. | 9.45 Million USD | -10034.592% |
| Genprex, Inc. | 31.06 Million USD | -2985.095% |
| Apogee Therapeutics, Inc. | 93 Million USD | -930.341% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -410.995% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -1065.809% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -125161.176% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -17492.478% |
| OKYO Pharma Limited | 8243.57 USD | -11624087.094% |
| Savara Inc. | 15.74 Million USD | -5986.046% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -5389.191% |
| Curis, Inc. | 58.35 Million USD | -1542.101% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -18716.893% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -3446.177% |
| BeiGene, Ltd. | 3.28 Billion USD | 70.844% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -523.648% |
| Erasca, Inc. | 141.52 Million USD | -577.087% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -21067.517% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -21067.517% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -2148.933% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -6570.249% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1336.632% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -2107.233% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -360.408% |
| Adicet Bio, Inc. | 152.03 Million USD | -530.269% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -124.072% |
| Aditxt, Inc. | 25.95 Million USD | -3592.562% |
| Adagene Inc. | 41.83 Million USD | -2190.741% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -13008.552% |
| Quantum-Si incorporated | 111.65 Million USD | -758.191% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -6473.352% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2575.027% |
| Compugen Ltd. | 43.97 Million USD | -2079.273% |
| Generation Bio Co. | 144.46 Million USD | -563.299% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1054.099% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -1008.314% |
| Invivyd, Inc. | 205.75 Million USD | -365.723% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -1227.967% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -10117.493% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -1173.352% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -9215.136% |
| 2seventy bio, Inc. | 289.88 Million USD | -230.559% |
| Instil Bio, Inc. | 85.78 Million USD | -1017.034% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -7381.703% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -84358.39% |
| GeoVax Labs, Inc. | 6.02 Million USD | -15811.997% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -2508.754% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -824.04% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -462.755% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -24.817% |
| Evaxion Biotech A/S | 22.27 Million USD | -4202.865% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -606.965% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -307.97% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1098.634% |
| Cingulate Inc. | 22.75 Million USD | -4110.378% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 12890.283% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2045.315% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1443.719% |
| Clearmind Medicine Inc. | 8.74 Million USD | -10862.243% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1039.794% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -32571.425% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -850.388% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -151.842% |
| ImmunityBio, Inc. | 362.87 Million USD | -164.073% |
| Korro Bio, Inc. | 84.53 Million USD | -1033.565% |
| Kineta, Inc. | 21.15 Million USD | -4429.438% |
| BioVie Inc. | 31.95 Million USD | -2899.192% |
| Codexis, Inc. | 66.51 Million USD | -1340.585% |
| Celularity Inc. | 215.05 Million USD | -345.577% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -5787.491% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -322.842% |
| Virax Biolabs Group Limited | 6.54 Million USD | -14536.303% |
| Cibus, Inc. | 320.3 Million USD | -199.167% |
| IN8bio, Inc. | 30.33 Million USD | -3058.678% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -651.031% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -149626.25% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -22.917% |
| Eyenovia, Inc. | 25.4 Million USD | -3671.673% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -582.926% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -17128.479% |
| Elevation Oncology, Inc. | 45.44 Million USD | -2008.588% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1110.933% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1987.686% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -342.791% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -9523.863% |
| Moolec Science SA | 52.75 Million USD | -1716.563% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1467.353% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1958.977% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -918.633% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1876.87% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -10172.961% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -4134.689% |
| Humacyte, Inc. | 23.49 Million USD | -3978.172% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1095.837% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -6490.426% |
| Genelux Corporation | 24.33 Million USD | -3837.736% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2724.774% |
| Notable Labs, Ltd. | 14.77 Million USD | -6387.8% |
| Immunovant, Inc. | 282.7 Million USD | -238.952% |
| Quantum-Si incorporated | 111.65 Million USD | -758.191% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -4405.798% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -839.348% |
| Acasti Pharma Inc. | 11.3 Million USD | -8379.32% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -4080.636% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -2215.504% |
| PepGen Inc. | 84.76 Million USD | -1030.463% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -4085.037% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2828.136% |
| Immuneering Corporation | 58.41 Million USD | -1540.474% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -18725.218% |
| Belite Bio, Inc | 31.66 Million USD | -2925.919% |
| XOMA Corporation | 46.46 Million USD | -1962.389% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1318.576% |
| Bionomics Limited | 17.89 Billion USD | 94.644% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2785.673% |
| uniQure N.V. | 285.08 Million USD | -236.126% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -13008.552% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -393.416% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2850.544% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -11432.991% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -3159.901% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -17128.479% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6643.476% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -10680.155% |
| Altimmune, Inc. | 30.55 Million USD | -3036.039% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1255.314% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2785.673% |
| Peak Bio, Inc. | 1249.13 USD | -76713132.41% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -1192.833% |
| Benitec Biopharma Inc. | 22.38 Million USD | -4181.333% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -294.034% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -3257.208% |
| Zura Bio Limited | 62.63 Million USD | -1429.819% |
| PolyPid Ltd. | 21.04 Million USD | -4453.329% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -3257.208% |
| argenx SE | 1.53 Billion USD | 37.514% |
| Immunome, Inc. | 122.82 Million USD | -680.205% |
| Verona Pharma plc | 67.15 Million USD | -1326.999% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -3601.943% |
| Shattuck Labs, Inc. | 93.61 Million USD | -923.616% |
| CervoMed Inc. | 14.95 Million USD | -6306.357% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -11115.449% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1778.918% |
| Moolec Science SA | 52.75 Million USD | -1716.563% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -5725.768% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1125.538% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -1000.916% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -7514.207% |
| Achilles Therapeutics plc | 75.25 Million USD | -1173.335% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -32571.425% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1621.826% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1783.386% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1349.716% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1670.497% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -2010.26% |
| Beam Therapeutics Inc. | 554.19 Million USD | -72.908% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -285.63% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1878.666% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -925.105% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1047.204% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -7513.06% |
| NeurAxis, Inc. | 8.82 Million USD | -10763.013% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -112.475% |
| Lumos Pharma, Inc. | 38.66 Million USD | -2378.334% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -3515.697% |
| Palisade Bio, Inc. | 13.32 Million USD | -7094.054% |
| Nutriband Inc. | 5.73 Million USD | -16611.594% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -990.281% |
| Neurogene Inc. | 55.58 Million USD | -1623.995% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -11238.871% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -890.847% |
| Athira Pharma, Inc. | 125.46 Million USD | -663.751% |
| HCW Biologics Inc. | 21.02 Million USD | -4457.114% |
| XOMA Corporation | 46.46 Million USD | -1962.389% |
| Nektar Therapeutics | 190.9 Million USD | -401.955% |
| Arvinas, Inc. | 480 Million USD | -99.635% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -42039.87% |
| Merus N.V. | 200.49 Million USD | -377.943% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -827.142% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2667.903% |
| Rezolute, Inc. | 70.38 Million USD | -1261.399% |
| Clene Inc. | 41.07 Million USD | -2233.036% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -5750.655% |
| BeyondSpring Inc. | 24.86 Million USD | -3753.803% |
| Synlogic, Inc. | 58.53 Million USD | -1537.135% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -5255.734% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -21232.324% |
| Peak Bio, Inc. | 1249.13 USD | -76713132.41% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1485.296% |
| Krystal Biotech, Inc. | 160.42 Million USD | -497.315% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -254.079% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -175.329% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -44330.514% |
| MannKind Corporation | 125.59 Million USD | -662.955% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1032.989% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -9833.119% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -969.461% |
| Gossamer Bio, Inc. | 183.75 Million USD | -421.47% |
| CohBar, Inc. | 12.38 Million USD | -7635.107% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1789.141% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3374.179% |
| Legend Biotech Corporation | 583.14 Million USD | -64.324% |
| Mural Oncology plc | 192.07 Million USD | -398.903% |
| Disc Medicine, Inc. | 91.12 Million USD | -951.575% |
| Champions Oncology, Inc. | 28.11 Million USD | -3308.922% |
| REGENXBIO Inc. | 321.15 Million USD | -198.374% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -17773.646% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1618.646% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -2359.528% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -737.944% |
| Vaxart, Inc. | 90.72 Million USD | -956.2% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -11147.032% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -2139.207% |
| Cellectis S.A. | 97.32 Million USD | -884.636% |
| Longeveron Inc. | 21.25 Million USD | -4409.402% |
| Repare Therapeutics Inc. | 167.35 Million USD | -472.577% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 29.583% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1166.77% |
| Revolution Medicines, Inc. | 498.76 Million USD | -92.124% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -14305.412% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -2080.116% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -1184.687% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1276.101% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -8564.087% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 79.932% |
| Denali Therapeutics Inc. | 527.23 Million USD | -81.751% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -10969.484% |
| Veru Inc. | 101.34 Million USD | -845.501% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -3993.852% |
| Cingulate Inc. | 22.75 Million USD | -4110.378% |
| Passage Bio, Inc. | 108.38 Million USD | -784.082% |
| Context Therapeutics Inc. | 25.07 Million USD | -3721.891% |
| Exicure, Inc. | 14.07 Million USD | -6707.673% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -365.024% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -2112.993% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -10341.514% |
| Nuvalent, Inc. | 149.49 Million USD | -541.003% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -11778.761% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -824.504% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -4367.565% |
| OmniAb, Inc. | 83.89 Million USD | -1042.199% |
| Anew Medical, Inc. | 1.3 Million USD | -73563.73% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2824.698% |
| Lipocine Inc. | 15.08 Million USD | -6254.371% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1298.637% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1158.336% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2276.943% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -734.398% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -4180.951% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -44.283% |
| Ocugen, Inc. | 71.56 Million USD | -1238.952% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -920.868% |
| Q32 Bio Inc. | 92.68 Million USD | -933.932% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -4425.588% |
| Alumis Inc. Common Stock | 158.17 Million USD | -505.819% |
| Equillium, Inc. | 50.6 Million USD | -1793.546% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1435.506% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -6791.117% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -4979.473% |
| Dominari Holdings Inc. | 23.83 Million USD | -3920.34% |
| Edesa Biotech, Inc. | 9.22 Million USD | -10290.037% |
| vTv Therapeutics Inc. | 11.9 Million USD | -7947.77% |
| Bio-Techne Corporation | 563.03 Million USD | -70.192% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -134.402% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -256.549% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -624.425% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -6549.421% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -485.383% |
| Nkarta, Inc. | 131.65 Million USD | -627.875% |
| BioCardia, Inc. | 12.12 Million USD | -7805.684% |
| Iterum Therapeutics plc | 47.46 Million USD | -1918.724% |